Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
出版年份 2023 全文链接
标题
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
作者
关键词
-
出版物
BMC CANCER
Volume 23, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-05-17
DOI
10.1186/s12885-023-10917-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: a real-world study
- (2021) Debora Basile et al. BREAST
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials
- (2021) Ghulam Rehman Mohyuddin et al. JAMA Network Open
- Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer
- (2021) John Sharp et al. JAMA Network Open
- Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
- (2020) Talal Hilal et al. JAMA Internal Medicine
- Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
- (2020) Nathalie Baize et al. LANCET ONCOLOGY
- Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World
- (2019) S. Karim et al. CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- When is crossover desirable in cancer drug trials and when is it problematic?
- (2018) A Haslam et al. ANNALS OF ONCOLOGY
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
- (2018) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
- (2018) Vanesa Gregorc et al. LANCET ONCOLOGY
- Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015
- (2017) Susan Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hard-Wired Bias
- (2015) Vinay Prasad et al. MAYO CLINIC PROCEEDINGS
- The misguided ethics of crossover trials
- (2013) Vinay Prasad et al. Contemporary Clinical Trials
- Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint
- (2011) Sara A. Hurvitz CANCER TREATMENT REVIEWS
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now